Healthcare sector is screaming cheap

=== SUMMARY === - Post argues healthcare sector’s S&P market cap share has collapsed to 1994-like lows despite rising GDP spending (10%→21% since 1994). - Author draws a historical parallel to the 1994 Clinton price‑control scare that was thwarted, leading to a pharma surge; sees similar opportunity today. - Quality assessment: Well-researched DD with historical data and sector‑level analysis, though individual stock picks are subjective. === SENTIMENT === BULLISH === TRADE IDEAS === XLV - LONG | confidence: 0.75 | sentiment: +0.70 Speaker: u/mrmrmrj Thesis: 1. THE FACT: Healthcare spending as % of GDP is in a long‑term uptrend (10%→21%), but XLV’s S&P weight dropped from 16% to 10%, near 1994 lows. 2. THE BRIDGE: When the GDP share inflects up, the market‑cap share has historically surged. Maximum pessimism now resembles the 1994‑1996 pharma rally catalyst. 3. THE VERDICT: Buying the sector ETF XLV bets on mean reversion as aging demographics and policy fears fade, capturing the entire cheap sector. 4. RISKS: Renewed price‑control legislation (e.g., IRA expansion), recession cutting healthcare spending, or a tech/AI bubble stealing capital. Timeframe: medium-term Key Points: - Sector weight near historic low vs GDP share - Aging population secular tailwind intact - LLY & JNJ strong but rest of sector cheap MDT - LONG | confidence: 0.70 | sentiment: +0.70 Speaker: u/mrmrmrj Thesis: 1. THE FACT: MDT (#16 in XLV holdings) “just rolled over like a dying bird,” implying deep undervaluation within a cheap sector. 2. THE BRIDGE: Medtronic is a diversified med‑tech bellwether; if the sector mean‑reverts, laggards like MDT often see outsized gains. 3. THE VERDICT: A contrarian pick on a beaten‑down quality name with a strong historical franchise in medical devices. 4. RISKS: Regulatory headwinds (device taxes, FDA delays), competitive pressure from newer players, or continued margin compression. Timeframe: medium-term Key Points: - “Died bird” pattern suggests extreme pe